PPMI is a landmark study launched by The Michael J. Fox Foundation in 2010 to deepen knowledge of Parkinson's and to better understand its onset and progression to speed the development of new treatments.
Collecting and Sharing Parkinson's Information
Through PPMI, more than 1,400 participants — people with and without Parkinson’s disease (PD) — are completing clinical exams, undergoing brain scans and contributing biological samples in pursuit of a cure. Because PPMI is an observational study, its research volunteers do not take any experimental drug or placebo. Rather, they agree to undergo clinical assessments, contributing data and samples over at least five years. Monitoring changes in volunteers with and without PD over time will help researchers understand and measure the onset and progression of Parkinson's disease.
PPMI is sponsored by The Michael J. Fox Foundation and funded by the Foundation in partnership with biotech and pharmaceutical companies, nonprofit organizations, and individual donors.
Growing the Study with More Partners
In 2020, PPMI began recruiting more volunteers, with and without PD, to help grow its already invaluable data set and biosample library. This expansion is imperative to accelerate earlier diagnosis and ground-breaking treatments that may benefit people with PD today and make disease prevention a reality for future generations.
The study is looking to enroll 4,000 people total including:
- people with recently diagnosed Parkinson’s;
- people with certain PD risk factors (e.g., family history, genetic mutation, sleep disorder);
- and people without Parkinson’s to act as control volunteers.
PPMI is also opening more sites, growing from 33 centers to 50 in 12 countries. See what sites are currently recruiting volunteers.
Pursuing Better Tests and Treatments
PPMI collects and analyzes different kinds of information over time to better understand how Parkinson’s begins and progresses.
A simple online system allows researchers around the globe to access study data and request samples for use in their complementary research. Scientists have downloaded PPMI data more than 6 million times, and the study has fielded more than 200 biosample requests. (Interested scientists can visit www.ppmi-info.org.)
The impact of PPMI is already felt across Parkinson’s research:
- Scientific Results: Analysis of PPMI data and samples has led to significant findings on, for example, brain imaging of dopamine loss in early PD and genetic variants associated with Parkinson’s. These results are building greater understanding of disease that can point to new tests and therapies. View list of PPMI publications.
- Standardization and Collaboration: PPMI’s rigorous standards for gathering, storing and analyzing data and biosamples have been adopted by other studies, allowing scientists to directly compare data and learn from more people. In fact, PPMI is a cornerstone of multiple large-scale collaborations, such as the Accelerating Medicines Partnership Parkinson’s disease (AMP PD) program.
- Trial Design: More than 15 trials of novel therapies to slow or stop Parkinson’s have used PPMI data to design their studies. PPMI data has helped researchers calculate how many people to enroll in new trials and how to evaluate them. And PPMI’s successful recruitment and retention of volunteers — including genetic mutation carriers — for a long, intensive study, have lent confidence to study sponsors.